Clinical Partnerships Target hospital systems and cancer centers with IncellDx’s single-cell molecular diagnostics to offer diagnostic services, prognostics, and potential companion diagnostics with pharma partners.

Cross Sell Opportunities Leverage past veterinary and canine circulating tumor cell work to enter veterinary oncology and translational research markets, offering cross sell of BioINK reagents and single-cell assays.

Strategic Alliances Build on Halo Diagnostics and other precision diagnostics partnerships to accelerate market access through co marketing and distribution agreements with established networks.

Platform Fit Position BioINK platform as a complementary workflow for existing labs, enabling per cell molecular detail analysis that can integrate with NGS or protein and RNA assays for richer diagnostics.

Growth Channels Capitalize on the California base and biotech clusters to pursue US academic medical centers and public health collaborations; explore international opportunities aligned with past UNICEF engagement.